

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-34. (Canceled)

35. (Currently Amended) A vector suitable for *in vitro* transgene delivery into mammalian cells, wherein said vector comprises a chimeric genetic construct comprising a transgene operably linked to at least two distinct posttranscriptional regulatory elements functional in mammalian cells, ~~at least one of said posttranscriptional regulatory elements each comprising all or a portion of a UTR region of a eukaryotic mRNA selected from a WPRE element, tau 3'UTR, TH3'UTR and APP5'UTR or a functional portion thereof.~~

36. (Previously Presented) The vector of claim 35, wherein at least one posttranscriptional regulatory element confers increased stability to mRNAs.

Claims 37-42. (Canceled)

43. (Currently Amended) The vector of claim [[39]]35, wherein said WPRE element comprises all or a functional fragment of SEQ ID NO: 1.

44. (Currently Amended) The vector of claim [[38]]35, wherein said APP5'UTR region comprises all or a functional fragment of SEQ ID NO: 2.

45. (Currently Amended) The vector of claim [[38]]35, wherein said tau3'UTR region comprises all or a functional fragment of SEQ ID NO: 3.

46. (Currently Amended) The vector of claim [[38]]35, wherein said TH3'UTR region comprises all or a functional fragment of SEQ ID NO: 4.

47. (Previously Presented) The vector of claim 35, wherein said vector further comprises a promoter controlling transcription of the transgene in said mammalian cells.

48. (Previously Presented) The vector of claim 35, wherein said vector further comprises a marker gene.

49. (Previously Presented) The vector of claim 35, wherein said vector further comprises a polyadenylation signal operably linked to said transgene.

50. (Previously Presented) The vector of claim 35, wherein said vector is selected from a plasmid and a recombinant virus.

51. (Previously Presented) The vector of claim 35, wherein said vector is selected from a replication-defective adenovirus, a replication-defective adeno-associated virus and a replication-defective retrovirus, including replication-defective lentiviruses.

52. (Previously Presented) The vector of claim 35, wherein the transgene is selected from a transgene coding for a growth factor, a neurotrophic factor, a cytokine, a ligand, a receptor, an immunoglobulin and an enzyme.

53. (Currently Amended) A recombinant cell comprising a chimeric genetic construct or a vector of claim 35 suitable for *in vitro* transgene delivery into mammalian cells, wherein said vector comprises a chimeric genetic construct comprising a

transgene operably linked to at least two distinct posttranscriptional regulatory elements functional in mammalian cells, each comprising a UTR region of a eukaryotic mRNA selected from a WPRE element, tau 3'UTR, TH3'UTR and APP5'UTR.

54. (Currently Amended) A composition comprising a ~~chimeric genetic construct or a vector of claim 35 suitable for *in vitro* transgene delivery into mammalian cells, wherein said vector comprises a chimeric genetic construct comprising a transgene operably linked to at least two distinct posttranscriptional regulatory elements functional in mammalian cells, each comprising a UTR region of a eukaryotic mRNA selected from a WPRE element, tau 3'UTR, TH3'UTR and APP5'UTR~~ or a recombinant cell comprising same and a pharmaceutically acceptable excipient or carrier.

55. (Previously Presented) The composition of claim 54 for treating a human disease.

56. (Previously Presented) The composition of claim 55, wherein said human disease is a neurodegenerative disease selected from Parkinson disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease and retinal degenerative diseases.

57. (Previously Presented) A method of expressing a transgene in a mammalian cell *in vitro* or *ex vivo*, the method comprising:

a) providing a chimeric genetic construct comprising said transgene operably linked to at least two distinct posttranscriptional regulatory elements, and

b) introducing said construct into mammalian cells, said introduction causing expression of said transgene in said mammalian cells.

58. (Currently Amended) The method of claim 57, comprising:

a) providing a vector according to claim 35 suitable for *in vitro* transgene delivery into mammalian cells, wherein said vector comprises a chimeric genetic construct comprising a transgene operably linked to at least two distinct posttranscriptional regulatory elements functional in mammalian cells, each comprising a UTR region of a eukaryotic mRNA selected from a WPRE element, tau 3'UTR, TH3'UTR and APP5'UTR, and

b) introducing said vector into mammalian cells, said introduction causing expression of said transgene in said mammalian cells.

59. (Previously Presented) The method of claim 57, wherein said mammalian cells are neural cells.

60. (Previously Presented) The method of claim 57, wherein said mammalian cells are fibroblasts.

61. (Previously Presented) The method of claim 57, wherein said mammalian cell is a human cell or a rodent cell.

62. (Previously Presented) The method of claim 57, wherein the chimeric genetic construct is introduced into mammalian cells by virus-mediated infection.

63. (Previously Presented) The method of claim 57, wherein the chimeric genetic construct is introduced into cells by plasmid-mediated transfection.

64. (Currently Amended) A method of expressing in vitro or ex vivo a transgene in glial cells, the method comprising:

- a) providing a chimeric genetic construct comprising said transgene operably linked to posttranscriptional regulatory elements comprising a WPRE element combined with a APP5'UTR or a portion thereof, and
- b) introducing said construct into glial cells, said introduction causing expression of said transgene in said glial cells.

65. (Currently Amended) A method of expressing in vitro or ex vivo a transgene in fibroblasts, the method comprising:

- a) providing a chimeric genetic construct comprising said transgene operably linked to posttranscriptional regulatory elements comprising a WPRE element combined with a APP5'UTR or a portion thereof, and
- b) introducing said construct into fibroblasts, said introduction causing expression of said transgene in said fibroblasts.

66. (Currently Amended) A method of expressing in vitro or ex vivo a transgene in neuronal cells, the method comprising:

- a) providing a chimeric genetic construct comprising said transgene operably linked to posttranscriptional regulatory elements comprising a WPRE element combined with a APP5'UTR and a tau3'UTR or a portion thereof, and
- b) introducing said construct into neuronal cells, said introduction causing expression of said transgene in said neuronal cells.

67. (Currently Amended) A method of expressing in vitro or ex vivo a transgene in neuronal cells, the method comprising:

- a) providing a chimeric genetic construct comprising said transgene operably linked to posttranscriptional regulatory elements comprising a WPRE element combined with a APP5'UTR, a tau3'UTR and a TH3'UTR or a portion thereof,
- b) introducing said construct into neuronal cells, said introduction causing expression of said transgene in said neuronal cells.